Condition: Ovarian Neoplasms · Breast Neoplasms · Pancreatic Intraductal Neoplasms · Sponsor: Eli Lilly and Company
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.
This description comes directly from the study's public registry record.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| Hoag Memorial Hospital Presbyterian | Newport Beach, California, United States | Recruiting |
| Stanford University Medical Center | Stanford, California, United States | Recruiting |
| Biogenix Molecular, LLC | Miami, Florida, United States | Recruiting |
| Moffitt | Tampa, Florida, United States | Recruiting |
| Indiana University (IU) School of Medicine | Indianapolis, Indiana, United States | Recruiting |
| United Theranostics | Glen Burnie, Maryland, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Not Yet Recruiting |
| Barbara Ann Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| BAMF Health Inc. | Grand Rapids, Michigan, United States | Recruiting |
| Mayo Clinic - Rochester | Rochester, Minnesota, United States | Not Yet Recruiting |
| Washington University School of Medicine in St. Louis | St Louis, Missouri, United States | Not Yet Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07213791